RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson

June 02, 2020

CARY, N.C., June 2Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMOTM (selpercatinib), the first drug approved by the U.S. Food and Drug Administration (FDA) specifically for patients with advanced RET-driven non-small cell lung cancer (NSCLC) and thyroid cancers.

RETEVMO, approved by the FDA on May 8, 2020, is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as well as adults and children 12 years and older with either advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). Crossing the blood-brain barrier, this drug shrinks tumors in parts of the central nervous system, including the brain. This is important to RET fusion-positive NSCLC patients because up to 50% can have tumors that metastasize to the brain.

“This is a critical new treatment option for patients with RET-driven lung and thyroid cancers because RETEVMO inhibits RET,” said Brandon Tom, vice president of Commercial Services with Biologics. “We’re proud to be able to work with Eli Lilly to help make this therapy available for patients to take at home.”

Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

Public Relations Contact